Short interest for Cogent Biosciences gives investors a sense of the degree to which investors are betting on the decline of Cogent Biosciences's stock. Short interest data is updated every two weeks.

Cogent Biosciences Stock (NASDAQ:COGT), Short Interest Report

Cogent Biosciences

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

COGT

MRNS

NMRA

PSNY

RARE

RDZN

TRMD

U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.

Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Intraday Update

ABNB

AKAM

ALSN

ANGI

AZTR

BGLC

BLNK

CART

CCTG

CEVA

CLNN

CNVS

COIN

DTSS

EEIQ

ELWS

ENGN

GLDD

GMBL

HCSG

HOOD

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

IREN

KTOS

Larimar Therapeutics, Inc. - Common Stock

LRMR

LYFT

MGOL

NUKK

QDEL

QRTEB

REZI

SNTG

Sony Group Corporation American Depositary Shares

SONY

SUNW

TSEM

UFCS

UPST

VBIV

Shares of  Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list its financial arm in October 2025.

Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Earnings

Eurozone

Commodities

Global

KTTA

Morgan Stanley Capital Protected Notes for S&P 500 Index

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Monday.

The Dow traded up 0.26% to 36,341.44 while the NASDAQ rose 0.12% to 14,421.98. The S&amp;P 500 also rose, gaining, 0.30% to 4,618.11.

Nasdaq Edges Higher; Macy&#39;s Shares Jump

Cogent Biosciences Inc

<p>Friday,&nbsp;<strong>Novavax Inc</strong>&nbsp;(NASDAQ:&nbsp;NVAX) entered a co-exclusive licensing agreement with&nbsp;<strong>Sanofi&nbsp;SA</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) for COVID-19 and flu-COVID-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g38752603/press-release-sanofi-and-novavax-announce-co-exclusive-licensing-agreement-to-co-commercialize-cov" rel="noreferrer noopener">19 combination vaccines</a>.</p>
<p>The terms of the agreement include:</p>
<ul>
<li>A co-exclusive license to co-commercialize Novavax&#8217;s current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and India, Japan, and South Korea where Novavax has existing partnership agreements).</li>
<li>Novavax has a sole license to its adjuvanted COVID-19 vaccine for use in combination with Sanofi&#8217;s flu vaccines, while Novavax retains the right to and is developing its own COVID-19-Influenza Combination vaccine candidate.</li>
<li>A non-exclusive license to use Novavax&#8217;s adjuvanted COVID-19 vaccine in combination with non-flu vaccines.</li>
<li>A non-exclusive license to use the Matrix-M adjuvant in vaccine products.</li>
</ul>
<p>Novavax will receive an upfront payment of $500&nbsp;million and up to $700&nbsp;million in development,&nbsp;regulatory, and launch milestones,&nbsp;up to $1.2 billion.</p>
<p>Starting in 2025, Sanofi will book sales of Novavax&#8217;s adjuvanted COVID-19 vaccine and&nbsp;will&nbsp;support&nbsp;certain&nbsp;R&amp;D, regulatory, and commercial expenses.</p>
<p>Novavax will receive tiered double-digit percentage royalty payments on sales by Sanofi.</p>
<p>Sanofi will be responsible for developing and commercializing any novel flu-COVID-19 combination vaccine containing a Sanofi flu vaccine.</p>
<p>Outside of the collaboration, each party may develop and commercialize&nbsp;their&nbsp;own&nbsp;flu-COVID-19 vaccines and adjuvanted products at&nbsp;their&nbsp;own cost.</p>
<p>Novavax is entitled to additional&nbsp;launch and&nbsp;sales milestones opportunities of up to&nbsp;$200&nbsp;million&nbsp;plus mid-single digit royalties for each additional Sanofi vaccine product developed under a non-exclusive license with Novavax&#8217;s Matrix-M adjuvant technology.</p>
<p>In addition, Sanofi will take a minority (less than 5%) of approximately $70 million&nbsp;equity&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/n38753054/novavax-reports-first-quarter-2024-financial-results-and-operational-highlights" rel="noreferrer noopener">investment&nbsp;in Novavax</a>.</p>
<p>Novavax reported a first-quarter EPS loss of $(1.05), down from a loss of $(3.41) a year ago, beating the consensus of $(1.06)&nbsp;</p>
<p>The company reported sales of $93.86 million, up from $80.95 million a year ago, missing the consensus of $101.16 million.</p>
<p>Novavax removes the going concern notice.</p>
<p>Novavax&nbsp;is prepared&nbsp;to initiate an additional cost reduction program to reduce 2025 R&amp;D and SG&amp;A expenses to below&nbsp;$500 million, a portion of which it expects to be reimbursed by Sanofi under the agreement, reflecting over $225 million&nbsp;reduction beyond prior stated targets.</p>
<p><strong>Guidance:</strong>&nbsp;Novavax updates 2024 combined revenue and Sanofi Agreement Payments Of $970 million-$1.17 billion versus prior&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/37367720/why-is-covid-19-vaccine-maker-novavax-stock-plunging-on-wednesday" rel="noreferrer noopener">guidance of $800 million-$1 billion</a>.</p>
<p><strong>Price Action:</strong> NVAX shares are up 121% at $9.88 during the premarket session at last check Friday.</p>
<p><em>Photo: Marco Verch from Flickr.</em></p>


Biotech

Large Cap

Guidance

Health Care

Contracts

General

NVAX

Some Breather For Novavax's COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi And Erases Doubts About Its Going Concern

<p>Mizuho  analyst Vamil Divan   maintains Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) with a Neutral and lowers the price target from $9 to $8.</p>


Price Target

Analyst Ratings

RVNC

Mizuho Maintains Neutral on Revance Therapeutics, Lowers Price Target to $8

<p>CBL &amp; Associates (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBL#NYSE">CBL</a>) reported quarterly losses of $(0.01) per share. This is a 116.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $129.12 million in sales this quarter. This is a 5.31 percent decrease over sales of $136.36 million the same period last year.</p>


CBL & Associates Q1 EPS $(0.01) Down From $0.06 YoY, Sales $129.12M Down From $136.36M YoY

<p>Mizuho  analyst John Baumgartner   maintains Nomad Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOMD#NYSE">NOMD</a>) with a Buy and raises the price target from $26 to $28.</p>


NOMD

Mizuho Maintains Buy on Nomad Foods, Raises Price Target to $28

<ul>
<li>ATR-12 has nanomolar inhibition of key protease <i>in vitro </i>that drives Netherton syndrome</li>
<li>Topical application of ATR-12 to <i>ex vivo </i>human skin results in superior LEKTI delivery compared to topical LEKTI application</li>
<li>ATR-12 reduces IL-36g, a pro-inflammatory cytokine that drives Netherton syndrome
<ul>
<li>Safe and well tolerated in minipigs</li>
</ul>
</li>
</ul>


Events

Azitra Reports Preclinical Data Of ATR-12 And Clinical Design On Netherton Syndrome At ASGCT Annual Meeting

INTS

Intensity Therapeutics Signs Collaboration Agreement With The Swiss Group For Clinical Cancer Research SAKK To Conduct Phase 2 Breast Cancer Trial In Europe For INT230-6

<p>Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent.  The company reported quarterly sales of $29.619 million which beat the analyst consensus estimate of $28.383 million by 4.35 percent.  This is a 15.91 percent decrease over sales of $35.222 million the same period last year.</p>


Earnings Beats

Telos Q1 2024 Adj EPS $(0.08) Beats $(0.11) Estimate, Sales $29.619M Beat $28.383M Estimate

<p>Mizuho  analyst Anthony Crowdell   maintains Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) with a Neutral and raises the price target from $132 to $217.</p>


Mizuho Maintains Neutral on Constellation Energy, Raises Price Target to $217

Management

BPOP

Popular Appoints Javier Ferrer As President And COO

AEMD

Aethlon Medical Announces Results From In Vitro Binding Study Of Hemopurifier In Removing Extracellular Vesicles From Cancer Patient Plasma

<ul>
<li>John Lawler, CFO and one of the architects of the Ford+ plan, taking on broader responsibilities as vice chair to help lead on future strategy choices, fully leverage partnerships, and liaise with leaders on industry-critical policy around the globe</li>
<li>Sherry House joining Ford in June with experience across automotive, tech and startups, with plan to become CFO early next year as company drives profitable growth across segments, particularly EVs, software and services</li>
</ul>
<p>Ford Motor Company today announced senior leadership moves designed to build on significant progress against its Ford+ plan and speed profitable growth through a more resilient business.</p>
<p><strong>John Lawler</strong>, Ford's CFO since October 2020, will initially continue in that role while also becoming vice chair, a position in which he will lead the company in areas critical to its long-term success.</p>
<p>Additionally, <strong>Sherry House</strong>, who most recently was CFO at electric vehicle maker Lucid Motors, is joining Ford as vice president, Finance, part of a plan to succeed Lawler as CFO in early 2025. In the meantime, she will oversee financial planning and analysis as well as the finance organizations for the company's automotive businesses: Ford Blue, Ford Pro and Ford Model e.</p>
<p>Both assignments are effective in early June.</p>


Ford Says Sherry House Joining In June With Experience Across Automotive, Tech And Startups, With Plan To Become CFO Early Next Year

Macro Economic Events

Econ #s

Economics

U.K. NIESR Monthly Gross Domestic Product (GDP) Tracker 0.7% Vs. 0.4% Prior

<p>Creative Realities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREX#NASDAQ">CREX</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.09) by 88.89 percent.  The company reported quarterly sales of $12.285 million which missed the analyst consensus estimate of $12.300 million by 0.12 percent.  This is a 23.54 percent increase over sales of $9.944 million the same period last year.</p>


Earnings Misses

CREX

Creative Realities Q1 2024 GAAP EPS $(0.01) Beats $(0.09) Estimate, Sales $12.285M Miss $12.300M Estimate

<p>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.47) by 6.38 percent.</p>


PRME

Prime Medicine Q1 2024 GAAP EPS $(0.44) Beats $(0.47) Estimate

MNDR

Mobile-Health Network Solutions Establishes Malaysia Subsidiary

<p>Brixmor Property Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>) ("Brixmor" or the "Company") announced today&nbsp;that James M. Taylor Jr. will return from his medical leave of absence and reassume his duties as the Company's Chief Executive Officer and President, effective May 20, 2024. Brian T. Finnegan, who has served as interim Chief Executive Officer and President, will continue in his position as Senior Executive Vice President and Chief Operating Officer.</p>


Brixmor Property Group CEO And President James M. Taylor To Return From Medical Leave Of Absence, Effective May 20, 2024

<p>During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a <a href="https://www.benzinga.com/yield-investments">high dividend payout</a>.</p>
<p>Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.</p>
<p>Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.</p>
<h3 class="wp-block-heading"><strong>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 5.96%</li>
<li><strong>Morgan Stanley </strong>analyst Terence Flynn maintained an Equal-Weight rating and increased the price target from $28 to $29 on May 2. This analyst has an accuracy rate of 70%.</li>
<li><strong>BMO Capital </strong>analyst Evan David Seigerman reiterated an Outperform rating and raised the price target from $33 to $36 on May 2. This analyst has an accuracy rate of 68%.</li>
<li><strong>Recent News:</strong> Pfizer has reportedly settled 10,000 lawsuits alleging it concealed the cancer risks associated with its Zantac heartburn medication, marking the largest resolution in the litigation.</li>
</ul>
<h3 class="wp-block-heading"><strong>Organon &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 5.46%</li>
<li><strong>Piper Sandler </strong>analyst DavidAmsellemmaintained an Overweight rating and raised the price target from $22 to $24 on April 29. This analyst has an accuracy rate of 66%.</li>
<li><strong>Morgan Stanley</strong> analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $27 to $22 on Oct. 11, 2023. This analyst has an accuracy rate of 70%.</li>
<li><strong>Recent News:</strong> Organon announced pricing of $1.0 billion senior notes offering.</li>
</ul>
<h3 class="wp-block-heading"><strong>Bristol-Myers Squibb Company </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li><strong>Dividend Yield:</strong> 5.36%</li>
<li><strong>BMO Capital </strong>analyst Evan Siegermanmaintained a Market Perform rating and cut the price target from $55 to $48 on April 26. This analyst has an accuracy rate of 60%.</li>
<li><strong>Wells Fargo </strong>analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $51 to $52 on April 18. This analyst has an accuracy rate of 77%.</li>
<li><strong>Recent News:</strong> On April 25, Bristol Myers Squibb posted first-quarter revenues of $11.9 billion, beating the consensus of $11.5 billion.</li>
</ul>
<p>Read More: <a href="https://www.benzinga.com/news/earnings/24/05/38753455/enbridge-funko-and-3-stocks-to-watch-heading-into-friday">Enbridge, Funko And 3 Stocks To Watch Heading Into Friday</a></p>


Dividends

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields

<p>Analysts' ratings for 3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) over the last quarter vary from bullish to bearish, as provided by 15 analysts.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $101.07, with a high estimate of $126.00 and a low estimate of $78.00. A 0.32% drop is evident in the current average compared to the previous average price target of $101.39. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715342462_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A clear picture of 3M's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wesley Brooks</td>
<td>HSBC</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$91.13</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Underperform</td>
<td>$87.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Damian Karas</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$111.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$98.00</td>
<td>$95.31</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$78.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$84.00</td>
<td>-</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$126.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$111.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$84.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to 3M. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of 3M compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for 3M's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Capture valuable insights into 3M's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MMM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on 3M analyst ratings.</strong></a></p>
<h2>Delving into 3M's Background</h2>
<p>3M is a multinational conglomerate that has operated since 1902, when it was known as Minnesota Mining and Manufacturing. The company is well known for its research and development laboratory and it leverages its science and technology across multiple product categories. As of the second quarter of 2024, 3M is organized across three business segments: safety and industrial, transportation and electronics, and consumer. Nearly 50% of the company's revenue comes from outside the Americas, with the safety and industrial segment constituting a plurality of net sales. Many of the company's tens of thousands of products touch and concern a variety of consumers and end markets.</p>
<h3>Financial Insights: 3M</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Negative Revenue Trend:</strong> Examining 3M's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately <strong>-0.35%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> 3M's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>11.6%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> 3M's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>19.19%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> 3M's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.75%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>4.55</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Unveiling 15 Analyst Insights On 3M

<p>6 analysts have expressed a variety of opinions on Essential Props Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPRT#NYSE">EPRT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Essential Props Realty, revealing an average target of $28.17, a high estimate of $29.00, and a low estimate of $26.00. Witnessing a positive shift, the current average has risen by 6.3% from the previous average price target of $26.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715342450_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Essential Props Realty. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$29.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Nicholas Joseph</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.50</td>
<td>$25.00</td>
</tr>
<tr>
<td>Simon Yarmak</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.50</td>
<td>$27.00</td>
</tr>
<tr>
<td>John Massocca</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$29.00</td>
<td>$27.50</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Eric Borden</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$29.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Essential Props Realty. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Essential Props Realty compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Essential Props Realty's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Essential Props Realty's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EPRT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Essential Props Realty analyst ratings.</strong></a></p>
<h2>Discovering Essential Props Realty: A Closer Look</h2>
<p>Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses.</p>
<h3>Essential Props Realty: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Essential Props Realty showcased positive performance, achieving a revenue growth rate of <strong>23.68%</strong> as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>45.27%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>1.51%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.96%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Essential Props Realty's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.52</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EPRT

Expert Ratings For Essential Props Realty

<p>In the preceding three months, 7 analysts have released ratings for Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $273.29, a high estimate of $290.00, and a low estimate of $250.00. Witnessing a positive shift, the current average has risen by 6.93% from the previous average price target of $255.57.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715342440_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Charles River among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$270.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>David Toung</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$268.00</td>
<td>$252.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Charles River. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Charles River compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Charles River's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Charles River's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CRL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Charles River analyst ratings.</strong></a></p>
<h2>Get to Know Charles River Better</h2>
<p>Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model &amp; services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery &amp; safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.</p>
<h3>Key Indicators: Charles River's Financial Health</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Charles River's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately <strong>-7.85%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Charles River's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>18.46%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Charles River's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>5.42%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Charles River's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.37%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.85</strong>, caution is advised due to increased financial risk.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Landscape: 7 Takes On Charles River

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cigna (CI – Research Report), Cogent Biosciences (...

Analysts Offer Insights on Healthcare Companies: Cigna (CI), Cogent Biosciences (COGT) and Canopy Growth (CGC)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cogent Biosciences (COGT – Research Report), Celldex...

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Celldex (CLDX) and Laboratory (LH)

Overall market sentiment has been high on Cogent Biosciences Inc (COGT)  stock lately. COGT receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Cogent Biosciences Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on COGT!See Full COGT ReportWhat i

Cogent Biosciences Inc (COGT) Stock: What Does the Chart Say Monday?

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Cogent Biosciences (COGT – Research Report) today and set a price target of $16.00. ...

Cogent Biosciences: A Strong Buy on Oncology Asset Potential and Favorable Market Dynamics

Cogent Biosciences EPS of -$0.62 misses by $0.11

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Cogent Biosciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/cogt-stock-quote/"><strong>COGT</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Cogent Biosciences reported earnings per share of -62 cents. This was below the analyst estimate for EPS of -51 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/cogt-stock-earnings-cogent-biosciences-for-q1-of-2024/">COGT Stock Earnings: Cogent Biosciences Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

COGT Stock Earnings: Cogent Biosciences Misses EPS for Q1 2024

Buy Recommendation for Cogent Biosciences Based on Promising Clinical Trials and Market Position

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cogent Biosciences (COGT – Research Report) and Inoz...

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Inozyme Pharma (INZY)

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 5/8/2024, According to Top Analysts

Leerink Partners analyst Andrew Berens has reiterated their bullish stance on COGT stock, giving a Buy rating on May 8. Andrew Berens has given his...

Analyst Issues Buy Rating on Cogent Biosciences Amid Clinical and Financial Milestones

CLDX

INDI

INZY

Press Releases

Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting

Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cogent Biosciences Stock (NASDAQ:COGT), Short Interest Report

People Also Watch